A vaccine against malaria: a substantial step forward

The Lancet

Volumn 373, Issue 9673, 2009, Pages 1411-1412

  Moorthy, Vasee ^a,b   Smith, Peter G ^c   Kieny, Marie Paule ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MALARIA VACCINE; PLASMODIUM FALCIPARUM VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; MALARIA; PRIORITY JOURNAL; VACCINATION;

EID: 64949201714     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60802-3     Document Type: Note

References (11)

1. Bejon P., Lusingu J., Olotu A., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359 (2008) 2521-2532
2. Abdulla S., Oberholzer R., Juma O., et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 359 (2008) 2533-2544
3. Alonso P.L., Sacarlal J., Aponte J.J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 (2004) 1411-1420
4. Smith P.G., and Milligan P.J. Malaria vaccine: 3 or 6 months' protection?. Lancet 365 (2005) 472-473
5. Bojang K.A., Milligan P.J.M., Pinder M., et al., for the RTS,S Malaria Vaccine Trial Team. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
6. Alonso P., Sacarlal J., Aponte J., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
7. Epstein J.E., Giersing B., Mullen G., Moorthy V., and Richie T.L. Malaria vaccines: are we getting closer?. Curr Opin Mol Ther 9 (2007) 12-24
8. Malaria Vaccine Technology Roadmap (Aug, 2006). http://www.malariavaccineroadmap.net/pdfs/Malaria_Vaccine_TRM_Final.pdf (accessed Nov 10, 2008).
9. Epstein J.E. What will a partly protective malaria vaccine mean to mothers in Africa?. Lancet 370 (2007) 1523-1524
10. Moorthy V., Reed Z., Smith P.G., and on behalf of the WHO Malaria Vaccine Advisory Committee (MALVAC). MALVAC 2008: measures of efficacy of malaria vaccines in phase 2b and phase 3 trials-scientific, regulatory and public health perspectives. Vaccine 27 (2009) 624-628
11. Moorthy V., Reed Z., Smith P.G., and on behalf of the WHO Study Group on Measures of Malaria Vaccine Efficacy. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 25 (2007) 5115-5123